The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis

The novel nitroimidazopyran agent (S)-PA-824 has potent antibacterial activity against Mycobacterium tuberculosis in vitro and in vivo and is currently in phase II clinical trials for tuberculosis (TB). In contrast to M. tuberculosis, where (R)-PA-824 is inactive, we report here that both enantiomer...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Stephen, Wyllie, Susan, Stojanovski, Laste, Perry, Meghan R., Simeons, Frederick R. C., Norval, Suzanne, Osuna-Cabello, Maria, De Rycker, Manu, Read, Kevin D., Fairlamb, Alan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2013
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811480/
https://www.ncbi.nlm.nih.gov/pubmed/23856774
http://dx.doi.org/10.1128/AAC.00722-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811480/
https://www.ncbi.nlm.nih.gov/pubmed/23856774
http://dx.doi.org/10.1128/AAC.00722-13

Ejemplares similares